EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 19, 2005--Chiron Corporation (NASDAQ:CHIR) today announced that an independent Data Monitoring Committee (DMC) has recommended the continuation of Chiron’s CAPTIVATE study, an ongoing Phase 3 clinical trial of tifacogin for the treatment of patients with severe community-acquired pneumonia. The DMC made its recommendation following a planned interim analysis of clinical data from the study. The study data remains blinded to Chiron, and detailed analysis will not be available until the trial has been completed. No safety concerns were identified by the committee, confirming safety assessments conducted when patient enrollment reached 300 and again at 600.
